WARRANTS TO PURCHASE COMMON STOCK (Details Narrative) |
3 Months Ended |
|---|---|
|
Mar. 31, 2025
$ / shares
shares
| |
| Class of Warrant or Right [Line Items] | |
| Number of warrants that became exercisable | shares | 10,884 |
| Number of warrants that became exercisable upon FDA acceptance of NDA filing | shares | 5,758 |
| Number of warrants expired | shares | 1 |
| Warrants One [Member] | |
| Class of Warrant or Right [Line Items] | |
| Exercise price of warrants expired (in dollars per share) | $ / shares | $ 1,056 |
| Warrants Two [Member] | |
| Class of Warrant or Right [Line Items] | |
| Exercise price of warrants expired (in dollars per share) | $ / shares | 1,776 |
| Warrants Three [Member] | |
| Class of Warrant or Right [Line Items] | |
| Exercise price of warrants expired (in dollars per share) | $ / shares | $ 364,800 |
| X | ||||||||||
- Definition The exercise price of expired warrants. No definition available.
|
| X | ||||||||||
- Definition Net number of non-option equity instruments that became exercisable. No definition available.
|
| X | ||||||||||
- Definition Net number of non-option equity instruments that became exercisable upon FDA acceptance of NDA filing. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Number of shares under non-option equity instrument agreements for which rights to exercise lapsed. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|